Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.

Por Henzen-Logmans, S. C., Berns, E. M., Klijn, J. G., van der Burg, M. E., Foekens, J. A.
Publicado em 1992

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer.

Por Berns, E. M., Klijn, J. G., Smid, M., van Staveren, I. L., Gruis, N. A., Foekens, J. A.
Publicado em 1995

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.

Por Berns, E. M., van Staveren, I. L., Look, M. P., Smid, M., Klijn, J. G., Foekens, J. A.
Publicado em 1998

Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence.

Por Abeln, E. C., Kuipers-Dijkshoorn, N. J., Berns, E. M., Henzen-Logmans, S. C., Fleuren, G. J., Cornelisse, C. J.
Publicado em 1995

Allelotype of 28 human breast cancer cell lines and xenografts

Por Harkes, I C, Elstrodt, F, Dinjens, W N M, Molier, M, Klijn, J G M, Berns, E M J J, Schutte, M
Publicado em 2003

Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.

Por Schuyer, M., van Staveren, I. L., Klijn, J. G., vd Burg, M. E., Stoter, G., Henzen-Logmans, S. C., Foekens, J. A., Berns, E. M.
Publicado em 1996

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

Por Schuyer, M, Burg, M E L van der, Henzen-Logmans, S C, Fieret, J H, Klijn, J G M, Look, M P, Foekens, J A, Stoter, G, Berns, E M J J
Publicado em 2001

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

Por Beelen, K., Opdam, M., Severson, T. M., Koornstra, R. H. T., Vincent, A. D., Hauptmann, M., van Schaik, R. H. N., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., Linn, S. C.
Publicado em 2013

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer

Por Lammers, L A, Mathijssen, R H J, van Gelder, T, Bijl, M J, de Graan, A-J M, Seynaeve, C, van Fessem, M A, Berns, E M, Vulto, A G, van Schaik, R H N
Publicado em 2010

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer

Por Trinh, X B, Tjalma, W A A, Vermeulen, P B, Van den Eynden, G, Van der Auwera, I, Van Laere, S J, Helleman, J, Berns, E M J J, Dirix, L Y, van Dam, P A
Publicado em 2009

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy

Por Kriege, M, Hollestelle, A, Jager, A, Huijts, P E A, Berns, E M, Sieuwerts, A M, Meijer-van Gelder, M E, Collée, J M, Devilee, P, Hooning, M J, Martens, J W M, Seynaeve, C
Publicado em 2014

Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features

Por Berns, E M J J, Staveren, I L van, Verhoog, L, Ouweland, A M W van de, Gelder, M Meijer-van, Meijers-Heijboer, H, Portengen, H, Foekens, J A, Dorssers, L C J, Klijn, J G M
Publicado em 2001

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer

Por Jansen, M. P. H. M., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodríguez-González, F. G., Heine, A. A. J., Martens, J. W., Sleijfer, S., Foekens, J. A., Berns, E. M. J. J.
Publicado em 2011